Marc Darrow MD,JD  Thank you for reading my article. To answer some of your questions:
Stem cell and PRP injections for musculoskeletal conditions are NOT FDA APPROVED. We do not treat disease. We do not offer stem cell IV treatments. There are no guarantees that these treatments will help you. Prior to our treatment, seek advice from your medical physician. There is controversy in the medical community about whether umbilical cord blood stem cells are alive or dead, and which type of stem cell may be appropriate. If you have questions please call our office at 310-231-7000

In the near future we will be publishing our research study: “Treatment of Ankle Osteoarthritis with Bone Marrow Concentrate Injections.” In this research we will present case histories of our patients who had bone marrow derived stem cell therapy for ankle osteoarthritis. We are also gathering data on the use of umbilical cord stem cell therapy in our patients with ankle osteoarthritis.

In this article I will be updating you on recent research findings.

A new study published in March 2019 (1) discusses the problem orthopedists and surgeons have in presenting treatment options to their patients with advanced ankle osteoarthritis. As many doctors and patients are aware, ankle osteoarthritis treatment protocols have no real guideline recommendations of its own. Researchers say most doctors treat an ankle problem as they would treat a knee or hip and follow hip or knee treatment protocols when treating the ankle. Is this really such a bad thing? It is when you consider that these are the same guidelines of conservative care protocols that ultimately lead to patient pain management programs until such time that the knee or hip can be ultimately replaced.The difference in treating an ankle like a hip or an ankle like a knee is that doctors feel that if conservative care options do not work for knee or hip osteoarthritis, there is a reasonably reliable surgical option in total joint replacement. The same reasonably reliable surgical option, researchers suggests, may not be available for ankle replacement.

Recent research in the British medical bulletin (2discuss the risks and rewards of ankle arthrodesis or ankle fusion and total ankle replacement.

  • Total ankle replacement while an accepted treatment for end-stage ankle osteoarthritis has a higher need for revision surgery than ankle fusion.
  • While surgical outcome results are gradually improving, Total ankle replacement cannot yet be recommended for the routine management of ankle osteoarthritis. 

In the medical journal Foot & ankle specialist, Duke university doctors wrote as the number of total ankle replacements performed has risen, so has the need for a specialty medicine to perform secondary or revision surgery to fix the primary ankle replacement failure.(3)

These are the people studied in this report:

  • 193 patients
  • The majority of the revision surgeries had:
    • hardware component loosening, frequently of the talar component (38%).
    • In the cases that were revised to an ankle fusion, 81% fused after their first fusion procedure.
    • The overall complication rate was 18.2%, whereas the overall nonunion rate was 10.6%.

Surgery can cause pain and complication in healthy ankle tissue

Research in the Journal of Foot and Ankle Surgery (4examined why a patient will still have chronic ankle pain following ankle replacement:

The researchers suggested:

  • “Total ankle replacement studies have focused on reporting complications that are directly observed clinically or radiographically, including wound problems, technical errors, implant loosening, subsidence, infection, bone fractures, and heterotopic ossification. However, patients can still experience unresolved pain even when these problems have been ruled out.”
  • The researchers then initiated a study to more clearly define the relative risk of injury to the anatomic structures in the posterior (rear) ankle during total ankle replacement. They found:
    • High rates of posterior structural injury from the surgery was found.
    • Pins inserted during the surgery represented a high risk of damage to the tibial nerve  posteromedial tendinous structures, in particular, the flexor digitorum longus tendon.
    • The proximal lateral pins were highly likely to encounter the Achilles tendon and the sural nerve.
  • The researchers concluded: “Our results support our hypothesis that the tibial neurovascular structures are at the greatest risk when preparing for and completing the bony resection, particularly with the medial and proximal cuts. Posterior ankle soft tissue structure injuries can occur during implantation but currently with unknown frequency and undetermined significance. Further study of posterior structural injuries could result in a more informed approach to post-total ankle replacement complications and management.”

The research on stem cell therapy for ankle osteoarthritis

As mentioned at the top of this article our paper “Treatment of Ankle Osteoarthritis with Bone Marrow Concentrate Injections,” is awaiting publication. There have been studies already published that suggest bone marrow derived stem cells are an effective treatment for ankle osteoarthritis patients.

December 2016 research in the Journal of experimental orthopaedics from doctors at the Steadman Philippon Research Institute (5) reviewed the research in the treatment of ankle osteoarthritis with bone marrow derived stem cells.

The goal of this study was to review outcomes of bone marrow aspirate concentrate (bone marrow derived stem cells) for the treatment of chondral (cartilage) defects and osteoarthritis of the talus of the ankle.

The researchers noted that there is not much research (at the time of this paper’s writing). . . Nonetheless, the evidence available showed varying degrees of beneficial results of bone marrow derived stem cell therapy for the treatment of ankle cartilage defects.

  • The researchers hypothesized that bone marrow aspirate concentrate may be useful in regeneration of tissue, enhancing the quality of cartilage repair. As a result, BMAC promotes a potentially healthy environment for hyaline cartilage growth and repair.

Research cited:

  • A 2009 study published in Clinical Orthopaedics and Related Research, reported that 94 % of patients returned to low impact sports activity at an average 4.4 months after bone marrow aspirate transplantation and 77 % of patients returned to high impact sports activity at an average 11.3 months. (6)
  • The same researchers in 2013 reported that 73 % of the 36 patients playing sports before surgery were able to return to sports. They also reported that 22 % of these 36 patients were able to return to sport, but at a lower level than before surgery. (7)
  • A 2011 study reported that 95 % of patients who had undergone bone marrow concentrate treatments  returned to their pre-symptom level of sporting activity at an average 13 weeks.(8)

A 2016 report in the Journal of experimental orthopaedics examined ways to save the ankle from fusion and replacement. In this study, Italian researchers discussed joint saving procedures such as:

  • Surgical procedures such as Arthroscopic debridement, arthrodiastasis, and osteotomy are the current joint sparing procedures, but, in the available studies, controversial results were achieved
  • Better results for patients they speculated could be achieved with Mesenchymal stem cells (MSCs). They write that stem cells may be a good solution to prevent or reverse ankle degeneration, due to their immunomodulatory features (able to control the catabolic joint environment) and their regenerative osteochondral capabilities (able to treat the chondral defects).(9)

In research from Korea, doctors found that after ankle surgery, such as osteotomy, ankle bones treated with bone marrow stem cell injections repaired significantly better. than those not treated (10)  My question is always, why not try it before the surgery?

A heavily cited and received 2015 study from doctors in Iran showed that stem cell treatments were able to regrow cartilage in ankles significant enough to improve function and pain levels in selected patients. Walking distances were shown to dramatically improve in the patient group.(11)

Can we help with your ankle pain?

Generally speaking, if your ankle is not frozen or locked up with bone spurs and can rotate, even thru the pain, then we can have a realistic expectation that we can provide some help. How much help? We can’t be sure until we do the examination.

Do you have questions? Ask Dr. Darrow


A leading provider of stem cell therapy, platelet rich plasma and prolotherapy
11645 WILSHIRE BOULEVARD SUITE 120, LOS ANGELES, CA 90025

PHONE: (800) 300-9300 or 310-231-7000

Stem cell and PRP injections for musculoskeletal conditions are not FDA approved. We do not treat disease. We do not offer IV treatments. There are no guarantees that this treatment will help you. Prior to our treatment, seek advice from your medical physician. There is controversy in the medical community about whether umbilical cord blood stem cells are alive or dead, and which type of stem cell may be appropriate.

Neither Dr. Darrow, nor any associate, offer medical advice from this transmission. This information is offered for educational purposes only. The transmission of this information does not create a physician-patient relationship between you and Dr. Darrow or any associate. We do not guarantee the accuracy, completeness, usefulness or adequacy of any resource, information, product, or process available from this transmission. We cannot be responsible for the receipt of your email since spam filters and servers often block their receipt. If you have a medical issue, please call our office. If you have a medical emergency, please call 911.


Paterson KL, Gates L. Clinical Assessment and Management of Foot and Ankle Osteoarthritis: A Review of Current Evidence and Focus on Pharmacological Treatment. Drugs & aging. 2019 Jan 25:1-9.
Maffulli N, Longo UG, Locher J, Romeo G, Salvatore G, Denaro V. Outcome of ankle arthrodesis and ankle prosthesis: a review of the current status. British Medical Bulletin. 2017 Nov 23:1-22.
Gross C, Erickson BJ, Adams SB, Parekh SG. Ankle arthrodesis after failed total ankle replacement: a systematic review of the literature. Foot & ankle specialist. 2015 Apr;8(2):143-51.
4. Reb CW, McAlister JE, Hyer CF, Berlet GC. Posterior Ankle Structure Injury During Total Ankle Replacement. J Foot Ankle Surg. 2016 Jun 9. [Google Scholar]
5 Chahla J, Cinque ME, Schon JM, et al. Bone marrow aspirate concentrate for the treatment of osteochondral lesions of the talus: a systematic review of outcomes. Journal of Experimental Orthopaedics. 2016;3:33. doi:10.1186/s40634-016-0069-x.
6 Giannini S, Buda R, Vannini F, Cavallo M, Grigolo B. One-step Bone Marrow-derived Cell Transplantation in Talar Osteochondral Lesions. Clinical Orthopaedics and Related Research. 2009;467(12):3307-3320. doi:10.1007/s11999-009-0885-8.
7 Giannini S, Buda R, Battaglia M, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G, Vannini F. One-step repair in talar osteochondral lesions: 4-year clinical results and t2-mapping capability in outcome prediction. The American journal of sports medicine. 2013 Mar;41(3):511-8.
8 Kennedy JG, Murawski CD. The Treatment of Osteochondral Lesions of the Talus with Autologous Osteochondral Transplantation and Bone Marrow Aspirate Concentrate: Surgical Technique. Cartilage. 2011 Oct;2(4):327-36. doi: 10.1177/1947603511400726. PMID: 26069591; PMCID: PMC4297142.
9. Castagnini F, Pellegrini C, Perazzo L, Vannini F, Buda R. J Exp Orthop. 2016 Dec;3(1):3. doi: 10.1186/s40634-016-0038-4. Epub 2016 Jan 15. Joint sparing treatments in early ankle osteoarthritis: current procedures and future perspectives.
10 Kim YS, Lee M, Koh YG. Additional mesenchymal stem cell injection improves the outcomes of marrow stimulation combined with supramalleolar osteotomy in varus ankle osteoarthritis: short-term clinical results with second-look arthroscopic evaluation. Journal of Experimental Orthopaedics. 2016;3:12. doi:10.1186/s40634-016-0048-2.
11 Emadedin M, Ghorbani Liastani M, Fazeli R, et al.Long-Term Follow-up of Intra-articular Injection of Autologous Mesenchymal Stem Cells in Patients with Knee, Ankle, or Hip Osteoarthritis. Arch Iran Med. 2015 Jun;18(6):336-44. doi: 015186/AIM.003.